136 related articles for article (PubMed ID: 17848810)
1. Docetaxel weekly with metastatic breast cancer.
Twelves C
Onkologie; 2007 Sep; 30(8-9):407-8. PubMed ID: 17848810
[No Abstract] [Full Text] [Related]
2. Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
Warm M; Nawroth F; Ohlinger R; Valter M; Pantke E; Mallmann P; Harbeck N; Kates R; Thomas A
Onkologie; 2007 Sep; 30(8-9):436-41. PubMed ID: 17848815
[TBL] [Abstract][Full Text] [Related]
3. A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.
Maisano R; Mare M; Caristi N; Chiofalo G; Picciotto M; Carboni R; Mafodda A; La Torre F
J Chemother; 2005 Apr; 17(2):242-6. PubMed ID: 15920913
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel for metastatic breast cancer: two consecutive phase II trials.
Campora E; Colloca G; Ratti R; Addamo G; Coccorullo Z; Venturino A; Guarneri D
Anticancer Res; 2008; 28(6B):3993-5. PubMed ID: 19192662
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
Schröder CP; de Munck L; Westermann AM; Smit WM; Creemers GJ; de Graaf H; Stouthard JM; van Deijk G; Erjavec Z; van Bochove A; Vader W; Willemse PH
Eur J Cancer; 2011 Jun; 47(9):1355-62. PubMed ID: 21251813
[TBL] [Abstract][Full Text] [Related]
6. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
[TBL] [Abstract][Full Text] [Related]
7. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.
Montero A; Booser D; Esparza-Guerra L; Murray J; Rosales M; Hortobagyi G; Valero V
Drugs R D; 2005; 6(5):299-305. PubMed ID: 16128600
[No Abstract] [Full Text] [Related]
9. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Mrozek E; Ramaswamy B; Young D; Rhoades CA; Kendra K; Allen J; Moore T; Hauger M; Watson H; Merriman N; Nadella P; Villalona-Calero M; Shapiro CL
Clin Breast Cancer; 2006 Jun; 7(2):141-5. PubMed ID: 16800973
[TBL] [Abstract][Full Text] [Related]
11. Testing chemotherapy for breast cancer: timing is everything.
Hudis C
J Clin Oncol; 2005 Aug; 23(24):5434-6. PubMed ID: 16110004
[No Abstract] [Full Text] [Related]
12. [Low dose-intensity docetaxel monotherapy for patients with anthracycline-resistant metastatic breast cancer in poor physical status].
Liu ZF; Zhang XQ; Guo QS; Yang XG; Song SP; Wu N; Wang MY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):317-9. PubMed ID: 18788642
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V
Cancer; 2008 Apr; 112(7):1455-61. PubMed ID: 18300256
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
17. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
[TBL] [Abstract][Full Text] [Related]
18. Erosive conjunctival and corneal inflammatory changes in a patient receiving weekly docetaxel for breast cancer.
Chalvatzis N; Manthou ME; Tzamalis A; Hytiroglou P; Dimitrakos S
Ocul Immunol Inflamm; 2014 Apr; 22(2):164-6. PubMed ID: 23876214
[No Abstract] [Full Text] [Related]
19. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Aapro M; Tjulandin S; Bhar P; Gradishar W
Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for advanced breast cancer.
Goldfarb SB; Traina TA; Dickler MN
Womens Health (Lond); 2010 Jan; 6(1):17-25. PubMed ID: 20001867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
